title: Management of the myeloproliferative disorders : distinguishing data from dogma.
authors.affiliation: University Department of Haematology, Cambridge, UK.
authors.forename: Anthony R
authors.initials: AR
authors.lastname: Green
authors.forename: George S
authors.initials: GS
authors.lastname: Vassiliou
authors.forename: Natasha
authors.initials: N
authors.lastname: Curtin
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Campbell
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000209:etiology / Q000517:prevention & control; D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use; D000075202:Contraindications; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000175:diagnosis / Q000628:therapy*; D018962:Phlebotomy; D011087:Polycythemia Vera / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000188:drug therapy; D011379:Prognosis; D011799:Quinazolines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D013920:Thrombocythemia, Essential / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D019851:Thrombophilia / Q000188:drug therapy / Q000209:etiology
chemical_list: D000925:Anticoagulants; D016898:Interferon-alpha; D011799:Quinazolines; C021139:anagrelide; D006918:Hydroxyurea